Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$3.91 +8.8%	$2.80	$1.60 ▼ $15.04	$105.60M	1.84	104,549 shs	157,542 shs
CING Cingulate	$4.19 +5.0%	$4.55	$3.02 ▼ $11.88	$22.68M	-0.74	163,104 shs	131,694 shs
IVVD Invivyd	$0.52 -1.5%	$0.73	$0.35 ▼ $2.74	$62.49M	0.51	1.16 million shs	1.59 million shs
ORMP Oramed Pharmaceuticals	$2.14 +3.9%	$2.14	$1.82 ▼ $3.09	$87.75M	1.6	70,270 shs	59,277 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	0.00%	+24.03%	+28.10%	+27.93%	-64.64%
CING Cingulate	0.00%	+3.71%	-21.97%	+14.48%	-61.91%
IVVD Invivyd	0.00%	-26.45%	-35.79%	-30.51%	-40.76%
ORMP Oramed Pharmaceuticals	0.00%	+2.88%	-4.46%	+0.94%	-13.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	1.7116 of 5 stars	3.3	1.0	1.1	0.8	1.3
CING Cingulate	2.4439 of 5 stars	3.5	3.0	2.1	0.8	0.6
IVVD Invivyd	4.0058 of 5 stars	3.6	5.0	2.9	4.2	0.6
ORMP Oramed Pharmaceuticals	0.9756 of 5 stars	0.0	3.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	117.56% Upside
CING Cingulate	3.00	Buy	$26.25	526.49% Upside
IVVD Invivyd	3.25	Buy	$3.85	640.24% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest CING, ANRO, ORMP, and IVVD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$61.00 ➝ $62.00
8/18/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/15/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $3.00
8/8/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
CING Cingulate	N/A	N/A	N/A	N/A	$2.32 per share	N/A
IVVD Invivyd	$25.38M	2.46	N/A	N/A	$0.56 per share	0.93
ORMP Oramed Pharmaceuticals	$1.34M	65.48	N/A	N/A	$3.61 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.39	N/A	N/A	N/A	N/A	-44.34%	-36.73%	11/11/2025 (Estimated)
CING Cingulate	-$15.55M	-$4.10	N/A	N/A	N/A	N/A	-232.16%	-132.07%	11/6/2025 (Estimated)
IVVD Invivyd	-$169.93M	-$0.92	N/A	4.73	N/A	-238.33%	-177.89%	-90.96%	N/A
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.35	N/A	N/A	N/A	N/A	-19.37%	-18.28%	11/6/2025 (Estimated)

Latest CING, ANRO, ORMP, and IVVD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	CING Cingulate	-$0.82	-$1.09	-$0.27	-$1.09	N/A	N/A
8/14/2025	Q2 2025	IVVD Invivyd	-$0.04	-$0.12	-$0.08	-$0.12	$23.16 million	$11.79 million
8/14/2025	Q2 2025	ORMP Oramed Pharmaceuticals	-$0.04	-$0.05	-$0.01	$0.31	N/A	N/A
8/13/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.18	18.43	18.43
CING Cingulate	N/A	1.52	1.87
IVVD Invivyd	N/A	1.33	1.53
ORMP Oramed Pharmaceuticals	N/A	26.82	23.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CING Cingulate	41.31%
IVVD Invivyd	70.36%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	N/A
CING Cingulate	4.04%
IVVD Invivyd	25.40%
ORMP Oramed Pharmaceuticals	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.08 million	N/A	N/A
CING Cingulate	20	5.41 million	5.19 million	Not Optionable
IVVD Invivyd	100	120.14 million	89.63 million	Optionable
ORMP Oramed Pharmaceuticals	10	41.00 million	33.71 million	Optionable

CING, ANRO, ORMP, and IVVD Headlines

Recent News About These Companies

Oramed Pharm Approves Stock Incentive Plan Amendment

August 21 at 4:50 PM | tipranks.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results, Misses Expectations By $0.01 EPS

August 18, 2025 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?

August 15, 2025 | marketbeat.com

Oramed Pharmaceuticals (ORMP) to Release Earnings on Wednesday

August 7, 2025 | marketbeat.com

Zacks Small Cap Has Negative Outlook for ORMP Q2 Earnings

August 1, 2025 | marketbeat.com

With Substantial Liquidity, ORMP Has Generated Gains & Income From Investment Portfolio

July 29, 2025 | msn.com

BML Capital Management LLC Raises Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

July 26, 2025 | marketbeat.com

ORMP - Oramed Pharmaceuticals Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

ORMP - Oramed Pharmaceuticals Inc Executives - Morningstar

June 27, 2025 | morningstar.comM

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

June 27, 2025 | finance.yahoo.com

Oramed Pharm Extends Stock Buyback Program

May 21, 2025 | tipranks.com

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

May 17, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | finanznachrichten.de

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025 | globenewswire.com

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | prnewswire.com

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

April 3, 2025 | finance.yahoo.com

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

March 15, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Issues Letter to Shareholders

March 4, 2025 | prnewswire.com

OraMed Enters Global Licensing Deal for Lidocaine Product

March 1, 2025 | investing.com

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

February 27, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CING, ANRO, ORMP, and IVVD Company Descriptions

Alto Neuroscience NYSE:ANRO

$3.91 +0.32 (+8.83%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.90 -0.01 (-0.18%)

As of 08/22/2025 06:35 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Cingulate NASDAQ:CING

$4.19 +0.20 (+5.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.03 -0.16 (-3.82%)

As of 08/22/2025 07:28 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Invivyd NASDAQ:IVVD

$0.52 -0.01 (-1.48%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.52 +0.00 (+0.75%)

As of 08/22/2025 07:55 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.14 +0.08 (+3.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.13 -0.01 (-0.47%)

As of 08/22/2025 04:10 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time